背景:结直肠癌(CRC),现在是全球第二大最常见的恶性肿瘤,在年轻人中更为普遍。近几十年来,在开发抗结直肠癌药物方面取得了进展,包括细胞毒性化合物。
目的:需要新型抗癌药物来克服现有障碍。最近的一项研究调查了新型制剂在预防结直肠癌中的有效性。
方法:在本研究中,我们评估了一种由壳聚糖谷氨酸制成的新型脂质体,称为cyclo-Gly-L-DOPA(CG-Nio-CGLD)。我们利用CCK-8,侵袭试验评估了CG-Nio-CGLD的抗结直肠癌特性,MTT测定,流式细胞术,和细胞周期分析。使用定量实时PCR分析与凋亡相关的基因的转录。同时,使用MTT测定法评估纳米材料对癌症和正常细胞系的细胞毒性。需要新型抗癌药物来克服现有障碍。最近的一项研究调查了新开发的制剂在预防结直肠癌中的有效性。
结果:Nio-CGLD和CG-Nio-CGLD的球形平均直径为169.12±1.87和179.26±2.17nm,分别。Nio-CGLD和CG-Nio-CGLD的捕获效率(EE%)分别为63.12±0.51和76.43±0.34%,分别。在CG-Nio-CGLD组中,早期的百分比,迟到,坏死,活CL40细胞为341.93%,23.27%,9.32%,和25.48%。基因PP53、cas3和cas8的转录在治疗组中显著高于对照组(P>0.001)。此外,治疗组BCL2和survivin基因表达水平低于对照组(P<0.01)。此外,CG-Nio-CGLD制剂表现出生物相容的纳米级递送机制,并且对CCD841CoN参考细胞系显示出很小的细胞毒性。
结论:这些研究结果表明,基于壳聚糖的噪声体封装可以增强CG-Nio-CGLD制剂在抗癌中的有效性。
BACKGROUND: Colorectal cancer (CRC), now the second most prevalent malignant tumor worldwide, is more prevalent in young adults. In recent decades, there has been progress in creating anti-colorectal cancer medications, including cytotoxic compounds.
OBJECTIVE: Novel anticancer drugs are needed to surmount existing obstacles. A recent study investigated the effectiveness of novel formulations in preventing colorectal cancer.
METHODS: During this study, we assessed a new kind of niosome called cyclo-Gly-L-DOPA (CG-Nio-CGLD) made from chitosan glutamate. We evaluated the anti-colorectal cancer properties of CG-Nio-CGLD utilizing CCK-8, invasion assay, MTT assay, flow cytometry, and cell cycle analysis. The transcription of genes associated with apoptosis was analyzed using quantitative real-time PCR. At the same time, the cytotoxicity of nanomaterials on both cancer and normal cell lines was assessed using MTT assays. Novel anticancer drugs are needed to surmount existing obstacles. A recent study investigated the effectiveness of newly developed formulations in preventing colorectal cancer.
RESULTS: The Nio-CGLD and CG-Nio-CGLD were spherical mean diameters of 169.12 ± 1.87 and 179.26 ± 2.17 nm, respectively. Entrapment efficiency (EE%) measurements of the Nio-CGLD and CG-Nio-CGLD were 63.12 ± 0.51 and 76.43 ± 0.34%, respectively. In the CG-Nio-CGLD group, the percentages of early, late, necrotic, and viable CL40 cells were 341.93%, 23.27%, 9.32%, and 25.48%. The transcription of the genes PP53, cas3, and cas8 was noticeably higher in the treatment group compared to the control group (P > 0.001). Additionally, the treatment group had lower BCL2 and
survivin gene expression levels than the control group (P < 0.01). Additionally, CG-Nio-CGLD formulations demonstrated a biocompatible nanoscale delivery mechanism and displayed little cytotoxicity toward the CCD 841 CoN reference cell line.
CONCLUSIONS: These findings indicate that chitosan-based noisome encapsulation may enhance the effectiveness of CG-Nio-CGLD formulations in fighting cancer.